{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:06:09Z","timestamp":1761167169040,"version":"build-2065373602"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-025-02905-z","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:46:44Z","timestamp":1761040004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosis and treatment strategies for hereditary pancreatic cancer syndrome"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7050-2351","authenticated-orcid":false,"given":"Hiroyuki","family":"Matsubayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Kiyozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2905_CR1","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M et al (2023) Clinical practice guidelines for Pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol 28:493\u2013511","journal-title":"Int J Clin Oncol"},{"key":"2905_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00535-011-0457-z","volume":"46","author":"H Matsubayashi","year":"2011","unstructured":"Matsubayashi H (2011) Familial pancreatic cancer and hereditary syndromes: screening strategy for high-risk individuals. J Gastroenterol 46:1249\u20131259","journal-title":"J Gastroenterol"},{"key":"2905_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/gutjnl-2019-319352","volume":"69","author":"M Goggins","year":"2020","unstructured":"Goggins M, Overbeek KA, Brand R et al (2020) Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69:7\u201317","journal-title":"Gut"},{"key":"2905_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y et al (2017) Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA 318:825\u2013835","journal-title":"JAMA"},{"key":"2905_CR5","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1002\/cncr.31628","volume":"124","author":"R Brand","year":"2018","unstructured":"Brand R, Borazanci E, Speare V et al (2018) Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. Cancer 124:3520\u20133527","journal-title":"Cancer"},{"key":"2905_CR6","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","volume":"26","author":"S Yadav","year":"2020","unstructured":"Yadav S, Kasi PM, Bamlet WR et al (2020) Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma. Clin Cancer Res 26:6505\u20136512","journal-title":"Clin Cancer Res"},{"key":"2905_CR7","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1002\/cam4.2973","volume":"9","author":"C Cremin","year":"2020","unstructured":"Cremin C, Lee MK, Hong Q et al (2020) Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Med 9:4004\u20134013","journal-title":"Cancer Med"},{"key":"2905_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103033","volume":"60","author":"K Mizukami","year":"2020","unstructured":"Mizukami K, Iwasaki Y, Kawakami E et al (2020) Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBioMedicine 60:103033","journal-title":"EBioMedicine"},{"key":"2905_CR9","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000414","volume":"12","author":"PLS Uson Jr","year":"2021","unstructured":"Uson PLS Jr, Samadder NJ, Riegert-Johnson D et al (2021) Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study. Clin Transl Gastroenterol 12:e00414","journal-title":"Clin Transl Gastroenterol"},{"key":"2905_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/jnci\/djac069","volume":"114","author":"A Gardiner","year":"2022","unstructured":"Gardiner A, Kidd J, Elias MC et al (2022) Pancreatic ductal carcinoma risk associated with hereditary cancer-risk genes. J Natl Cancer Inst 114:996\u20131002","journal-title":"J Natl Cancer Inst"},{"key":"2905_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184447","author":"A Puccini","year":"2022","unstructured":"Puccini A, Ponzano M, Dalmasso B et al (2022) Clinical significance of germline pathogenic variants among 51 cancer predisposition genes in an unselected cohort of Italian pancreatic cancer patients. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14184447","journal-title":"Cancers (Basel)"},{"key":"2905_CR12","doi-asserted-by":"publisher","first-page":"11672","DOI":"10.1002\/cam4.5871","volume":"12","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Li X, Wang F et al (2023) Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications. Cancer Med 12:11672\u201311685","journal-title":"Cancer Med"},{"key":"2905_CR13","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1200\/JCO.22.00298","volume":"40","author":"M Dbouk","year":"2022","unstructured":"Dbouk M, Katona BW, Brand RE et al (2022) The multicenter cancer of pancreas screening study: impact on stage and survival. J Clin Oncol 40:3257\u20133266","journal-title":"J Clin Oncol"},{"key":"2905_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M et al (2019) Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"2905_CR15","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s00262-023-03397-4","volume":"72","author":"MH Storandt","year":"2023","unstructured":"Storandt MH, Tran N, Martin N et al (2023) Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden. Cancer Immunol Immunother 72:2515\u20132520","journal-title":"Cancer Immunol Immunother"},{"key":"2905_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s10038-022-01097-y","volume":"68","author":"H Matsubayashi","year":"2023","unstructured":"Matsubayashi H, Todaka A, Kawakami T et al (2023) Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. J Hum Genet 68:81\u201386","journal-title":"J Hum Genet"},{"key":"2905_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13053-024-00283-7","volume":"22","author":"Y Kiyozumi","year":"2024","unstructured":"Kiyozumi Y, Matsubayashi H, Todaka A et al (2024) Two Japanese families with familial pancreatic cancer with suspected pathogenic variants of CDKN2A: a case report. Hered Cancer Clin Pract 22:11","journal-title":"Hered Cancer Clin Pract"},{"key":"2905_CR18","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.pan.2023.10.017","volume":"23","author":"H Kitamura","year":"2023","unstructured":"Kitamura H, Morizane C, Tanabe N et al (2023) Clinical features of germline BRCA1\/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Pancreatology 23:964\u2013969","journal-title":"Pancreatology"},{"key":"2905_CR19","doi-asserted-by":"publisher","first-page":"74227","DOI":"10.18632\/oncotarget.12490","volume":"7","author":"E Takai","year":"2016","unstructured":"Takai E, Yachida S, Shimizu K et al (2016) Germline mutations in Japanese familial pancreatic cancer patients. Oncotarget 7:74227\u201374235","journal-title":"Oncotarget"},{"key":"2905_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.18.01489","volume":"37","author":"EM Stoffel","year":"2019","unstructured":"Stoffel EM, McKernin SE, Brand R et al (2019) Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol 37:153\u2013164","journal-title":"J Clin Oncol"},{"key":"2905_CR21","first-page":"603","volume":"17","author":"MA Tempero","year":"2019","unstructured":"Tempero MA (2019) NCCN guidelines updates: pancreatic cancer. J Natl Compr Canc Netw 17:603\u2013605","journal-title":"J Natl Compr Canc Netw"},{"key":"2905_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","volume":"21","author":"MB Daly","year":"2023","unstructured":"Daly MB, Pal T, Maxwell KN et al (2023) NCCN guidelines(R) insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024. J Natl Compr Canc Netw 21:1000\u20131010","journal-title":"J Natl Compr Canc Netw"},{"key":"2905_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","volume":"330","author":"AW Kurian","year":"2023","unstructured":"Kurian AW, Abrahamse P, Furgal A et al (2023) Germline genetic testing after cancer diagnosis. JAMA 330:43\u201351","journal-title":"JAMA"},{"key":"2905_CR24","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/OP.23.00447","volume":"20","author":"DCF Klatte","year":"2024","unstructured":"Klatte DCF, Starr JS, Clift KE et al (2024) Utilization and outcomes of multigene panel testing in patients with pancreatic ductal adenocarcinoma. JCO Oncol Pract 20:1081\u20131090","journal-title":"JCO Oncol Pract"},{"key":"2905_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jjco\/hyac046","volume":"52","author":"S Higashigawa","year":"2022","unstructured":"Higashigawa S, Matsubayashi H, Kiyozumi Y et al (2022) Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. Jpn J Clin Oncol 52:599\u2013608","journal-title":"Jpn J Clin Oncol"},{"key":"2905_CR26","unstructured":"Guidelines for diagnosis and treatment of hereditary breast and ovarian cancer: Kanehara Shuppan (Tokyo), Japanese Organization of Hereditary Breast and\nOvarian Cancer (JOHBOC), 3rd edition, 2024"},{"key":"2905_CR27","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa2211807","volume":"388","author":"Y Usui","year":"2023","unstructured":"Usui Y, Taniyama Y, Endo M et al (2023) Helicobacter pylori, Homologous recombination genes, and gastric cancer. N Engl J Med 388:1181\u20131190","journal-title":"N Engl J Med"},{"key":"2905_CR28","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.cgh.2020.12.007","volume":"20","author":"M Fujita","year":"2022","unstructured":"Fujita M, Liu X, Iwasaki Y et al (2022) Population-based screening for hereditary colorectal cancer variants in Japan. Clin Gastroenterol Hepatol 20:2132\u20132141","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2905_CR29","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","volume":"33","author":"S Holter","year":"2015","unstructured":"Holter S, Borgida A, Dodd A et al (2015) Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124\u20133129","journal-title":"J Clin Oncol"},{"key":"2905_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100032","volume":"6","author":"U Peretti","year":"2021","unstructured":"Peretti U, Cavaliere A, Niger M et al (2021) Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open 6:100032","journal-title":"ESMO Open"},{"key":"2905_CR31","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s10620-022-07733-z","volume":"68","author":"M Baz","year":"2023","unstructured":"Baz M, Gondran-Teiller V, Bressac B et al (2023) The frequency of germline BRCA and non-BRCA HR-gene-variants in a cohort of pancreatic cancer patients. Dig Dis Sci 68:1525\u20131528","journal-title":"Dig Dis Sci"},{"key":"2905_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y et al (2022) Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 8:871\u2013878","journal-title":"JAMA Oncol"},{"key":"2905_CR33","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","volume":"94","author":"MS Brose","year":"2002","unstructured":"Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365\u20131372","journal-title":"J Natl Cancer Inst"},{"key":"2905_CR34","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1086\/302853","volume":"66","author":"R Moslehi","year":"2000","unstructured":"Moslehi R, Chu W, Karlan B et al (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66:1259\u20131272","journal-title":"Am J Hum Genet"},{"key":"2905_CR35","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","unstructured":"Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310\u20136","journal-title":"J Natl Cancer Inst"},{"key":"2905_CR36","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1001\/jama.2009.1529","volume":"302","author":"F Kastrinos","year":"2009","unstructured":"Kastrinos F, Mukherjee B, Tayob N et al (2009) Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790\u20131795","journal-title":"JAMA"},{"key":"2905_CR37","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2017-314057","volume":"67","author":"P Moller","year":"2018","unstructured":"Moller P, Seppala TT, Bernstein I et al (2018) Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch Syndrome Database. Gut 67:1306\u20131316","journal-title":"Gut"},{"key":"2905_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41395-018-0414-z","volume":"114","author":"S Paiella","year":"2019","unstructured":"Paiella S, Capurso G, Cavestro GM et al (2019) Results of first-round of surveillance in individuals at high-risk of pancreatic cancer from the AISP (Italian Association for the Study of the Pancreas) registry. Am J Gastroenterol 114:665\u2013670","journal-title":"Am J Gastroenterol"},{"key":"2905_CR39","first-page":"163","volume":"118","author":"DK Bartsch","year":"2021","unstructured":"Bartsch DK, Matth\u00e4i E, Mintziras I et al (2021) The German National case collection for familial pancreatic cancer (FaPaCa). Dtsch Arztebl Int 118:163\u2013168","journal-title":"Dtsch Arztebl Int"},{"key":"2905_CR40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1136\/gutjnl-2020-323611","volume":"71","author":"KA Overbeek","year":"2022","unstructured":"Overbeek KA, Levink IJM, Koopmann BDM et al (2022) Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut 71:1152\u20131160","journal-title":"Gut"},{"key":"2905_CR41","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.22.00194","volume":"40","author":"DCF Klatte","year":"2022","unstructured":"Klatte DCF, Boekestijn B, Wasser M et al (2022) Pancreatic cancer surveillance in carriers of a germline CDKN2A pathogenic variant: yield and outcomes of a 20-year prospective follow-up. J Clin Oncol 40:3267\u20133277","journal-title":"J Clin Oncol"},{"key":"2905_CR42","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10689-024-00388-x","volume":"23","author":"J Earl","year":"2024","unstructured":"Earl J, Fuentes R, Sanchez MEC et al (2024) The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer. Fam Cancer 23:383\u2013392","journal-title":"Fam Cancer"},{"key":"2905_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.pan.2020.05.011","volume":"20","author":"W Greenhalf","year":"2020","unstructured":"Greenhalf W, Levy P, Gress T et al (2020) International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with the International Association of Pancreatology, the American Pancreatic Association, the Japan Pancreas Society, and European Pancreatic Club. Pancreatology 20:910\u2013918","journal-title":"Pancreatology"},{"key":"2905_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pan.2017.11.007","volume":"18","author":"A Kanno","year":"2018","unstructured":"Kanno A, Masamune A, Hanada K et al (2018) Multicenter study of early pancreatic cancer in Japan. Pancreatology 18:61\u201367","journal-title":"Pancreatology"},{"key":"2905_CR45","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.pan.2022.10.003","volume":"22","author":"J Nakahodo","year":"2022","unstructured":"Nakahodo J, Kikuyama M, Fukumura Y et al (2022) Focal pancreatic parenchyma atrophy is a harbinger of pancreatic cancer and a clue to the intraductal spreading subtype. Pancreatology 22:1148\u20131158","journal-title":"Pancreatology"},{"key":"2905_CR46","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/den.14240","volume":"34","author":"K Hanada","year":"2022","unstructured":"Hanada K, Shimizu A, Kurihara K et al (2022) Endoscopic approach in the diagnosis of high-grade pancreatic intraepithelial neoplasia. Dig Endosc 34:927\u2013937","journal-title":"Dig Endosc"},{"key":"2905_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1177\/2050640617752182","volume":"6","author":"M Signoretti","year":"2018","unstructured":"Signoretti M, Bruno MJ, Zerboni G et al (2018) Results of surveillance in individuals at high-risk of pancreatic cancer: a systematic review and meta-analysis. United Eur Gastroenterol J 6:489\u2013499","journal-title":"United Eur Gastroenterol J"},{"key":"2905_CR48","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.gastro.2021.11.021","volume":"162","author":"A Chhoda","year":"2022","unstructured":"Chhoda A, Vodusek Z, Wattamwar K et al (2022) Late-stage pancreatic cancer detected during high-risk individual surveillance: a systematic review and meta-analysis. Gastroenterology 162:786\u2013798","journal-title":"Gastroenterology"},{"key":"2905_CR49","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.pan.2018.04.002","volume":"18","author":"S Paiella","year":"2018","unstructured":"Paiella S, Salvia R, De Pastena M et al (2018) Screening\/surveillance programs for pancreatic cancer in familial high-risk individuals: a systematic review and proportion meta-analysis of screening results. Pancreatology 18:420\u2013428","journal-title":"Pancreatology"},{"key":"2905_CR50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/SLA.0000000000006094","volume":"279","author":"S Paiella","year":"2024","unstructured":"Paiella S, Secchettin E, Lionetto G et al (2024) Surveillance of individuals at high risk of developing pancreatic cancer: a prevalence meta-analysis to estimate the rate of low-yield surgery. Ann Surg 279:37\u201344","journal-title":"Ann Surg"},{"key":"2905_CR51","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2024.1930","volume":"10","author":"AL Blackford","year":"2024","unstructured":"Blackford AL, Canto MI, Dbouk M et al (2024) Pancreatic cancer surveillance and survival of high-risk individuals. JAMA Oncol 10:1087\u20131096","journal-title":"JAMA Oncol"},{"key":"2905_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.pan.2022.04.006","volume":"22","author":"S Hijioka","year":"2022","unstructured":"Hijioka S, Morizane C, Takaori K et al (2022) Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome: the Diamond study. Pancreatology 22:534\u2013538","journal-title":"Pancreatology"},{"key":"2905_CR53","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132\u20131138","journal-title":"Br J Cancer"},{"key":"2905_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100238","volume":"6","author":"G Orsi","year":"2021","unstructured":"Orsi G, Di Marco M, Cavaliere A et al (2021) Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open 6:100238","journal-title":"ESMO Open"},{"key":"2905_CR55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41416-022-02086-w","volume":"128","author":"G Orsi","year":"2023","unstructured":"Orsi G, Cavaliere A, Tortora G et al (2023) Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Br J Cancer 128:877\u2013885","journal-title":"Br J Cancer"},{"key":"2905_CR56","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S et al (2020) Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer 122:333\u2013339","journal-title":"Br J Cancer"},{"key":"2905_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00152","volume":"2","author":"KA Reiss","year":"2018","unstructured":"Reiss KA, Yu S, Judy R et al (2018) Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precis Oncol 2:1\u20139","journal-title":"JCO Precis Oncol"},{"key":"2905_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101895","volume":"80","author":"TF Rebelatto","year":"2019","unstructured":"Rebelatto TF, Falavigna M, Pozzari M et al (2019) Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev 80:101895","journal-title":"Cancer Treat Rev"},{"key":"2905_CR59","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M et al (2022) Overall survival results from the POLO trial: a phase III study of active maintenance Olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 40:3929\u20133939","journal-title":"J Clin Oncol"},{"key":"2905_CR60","unstructured":"National Comprehensive Cancer Network (2024) NCCN clinical practical guidelines in oncology. Pancreatic adenocarcinoma. ver.3. https:\/\/www.nccn.org\/2024"},{"key":"2905_CR61","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12885-022-09661-7","volume":"22","author":"S Amin","year":"2022","unstructured":"Amin S, Joo S, Nolte S et al (2022) Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. BMC Cancer 22:563","journal-title":"BMC Cancer"},{"key":"2905_CR62","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-22-3724","volume":"29","author":"V Florou","year":"2023","unstructured":"Florou V, Elliott A, Bailey MH et al (2023) Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC. Clin Cancer Res 29:3408\u20133417","journal-title":"Clin Cancer Res"},{"key":"2905_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00535-023-01986-9","volume":"58","author":"T Sakakida","year":"2023","unstructured":"Sakakida T, Ishikawa T, Doi T et al (2023) Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol 58:575\u2013585","journal-title":"J Gastroenterol"},{"key":"2905_CR64","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1200\/JCO.23.00561","volume":"41","author":"D Mandelker","year":"2023","unstructured":"Mandelker D, Marra A, Zheng-Lin B et al (2023) Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol 41:5151\u20135162","journal-title":"J Clin Oncol"},{"issue":"3","key":"2905_CR65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10689-024-00390-3","volume":"23","author":"H Matsubayashi","year":"2024","unstructured":"Matsubayashi H, Todaka A, Tsushima T et al (2024) The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier; case report and literature review. Fam Cancer 23(3):393\u2013398","journal-title":"Fam Cancer"},{"key":"2905_CR66","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112:1105\u20131113","journal-title":"Cancer Sci"},{"key":"2905_CR67","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","volume":"33","author":"M Maio","year":"2022","unstructured":"Maio M, Ascierto PA, Manzyuk L et al (2022) Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 33:929\u2013938","journal-title":"Ann Oncol"},{"key":"2905_CR68","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","volume":"37","author":"A Latham","year":"2019","unstructured":"Latham A, Srinivasan P, Kemel Y et al (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37:286\u2013295","journal-title":"J Clin Oncol"},{"key":"2905_CR69","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/GIM.0b013e31818fa2db","volume":"11","author":"GE Palomaki","year":"2009","unstructured":"Palomaki GE, McClain MR, Melillo S et al (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11:42\u201365","journal-title":"Genet Med"},{"key":"2905_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.3651","author":"CA O'Connor","year":"2024","unstructured":"O\u2019Connor CA, Harrold E, Lin D et al (2024) Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2024.3651","journal-title":"JAMA Oncol"},{"key":"2905_CR71","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMoa053493","volume":"354","author":"RA Barnetson","year":"2006","unstructured":"Barnetson RA, Tenesa A, Farrington SM et al (2006) Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 354:2751\u20132763","journal-title":"N Engl J Med"},{"key":"2905_CR72","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00375","volume":"6","author":"JW Harriman","year":"2022","unstructured":"Harriman JW, Espinel WF, Vagher J et al (2022) BRCA1\/2 variants identified through tumor genomic profiling: assessing genetic counseling outcomes. JCO Precis Oncol 6:e2100375","journal-title":"JCO Precis Oncol"},{"key":"2905_CR73","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/pon.4712","volume":"27","author":"M Underhill","year":"2018","unstructured":"Underhill M, Hong F, Lawerence J et al (2018) Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Psychooncology 27:1711\u20131718","journal-title":"Psychooncology"},{"key":"2905_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10897-005-9014-3","volume":"15","author":"R Resta","year":"2006","unstructured":"Resta R, Biesecker BB, Bennett RL et al (2006) A new definition of genetic counseling: National Society of Genetic Counselors\u2019 task force report. J Genet Couns 15:77\u201383","journal-title":"J Genet Couns"},{"key":"2905_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114240","volume":"284","author":"J Treml","year":"2021","unstructured":"Treml J, Schmidt V, Nagi M et al (2021) Pre-loss grief and preparedness for death among caregivers of terminally ill cancer patients: a systematic review. Soc Sci Med 284:114240","journal-title":"Soc Sci Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02905-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02905-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02905-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:01:41Z","timestamp":1761084101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02905-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":75,"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02905-z","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}